These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 28930171)

  • 1. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
    Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
    Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
    Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
    Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
    Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels.
    Haldrup C; Lynnerup AS; Storebjerg TM; Vang S; Wild P; Visakorpi T; Arsov C; Schulz WA; Lindberg J; Grönberg H; Egevad L; Borre M; Ørntoft TF; Høyer S; Sørensen KD
    Mol Oncol; 2016 Jun; 10(6):825-37. PubMed ID: 26905753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter hypomethylation and upregulation of trefoil factors in prostate cancer.
    Vestergaard EM; Nexø E; Tørring N; Borre M; Ørntoft TF; Sørensen KD
    Int J Cancer; 2010 Oct; 127(8):1857-65. PubMed ID: 20112343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.
    Haldrup C; Pedersen AL; Øgaard N; Strand SH; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Mol Oncol; 2018 Apr; 12(4):545-560. PubMed ID: 29465788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.
    Kristensen H; Haldrup C; Strand S; Mundbjerg K; Mortensen MM; Thorsen K; Ostenfeld MS; Wild PJ; Arsov C; Goering W; Visakorpi T; Egevad L; Lindberg J; Grönberg H; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Clin Cancer Res; 2014 Apr; 20(8):2169-81. PubMed ID: 24737792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
    Strand SH; Switnicki M; Moller M; Haldrup C; Storebjerg TM; Hedegaard J; Nordentoft I; Hoyer S; Borre M; Pedersen JS; Wild PJ; Park JY; Orntoft TF; Sorensen KD
    Oncotarget; 2017 Jan; 8(4):5774-5788. PubMed ID: 28052017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.
    Haldrup C; Mundbjerg K; Vestergaard EM; Lamy P; Wild P; Schulz WA; Arsov C; Visakorpi T; Borre M; Høyer S; Orntoft TF; Sørensen KD
    J Clin Oncol; 2013 Sep; 31(26):3250-8. PubMed ID: 23918943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer.
    Storebjerg TM; Strand SH; Høyer S; Lynnerup AS; Borre M; Ørntoft TF; Sørensen KD
    Clin Epigenetics; 2018 Aug; 10(1):105. PubMed ID: 30086793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
    Kristensen H; Thomsen AR; Haldrup C; Dyrskjøt L; Høyer S; Borre M; Mouritzen P; Ørntoft TF; Sørensen KD
    Oncotarget; 2016 May; 7(21):30760-71. PubMed ID: 27120795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.
    Uhl B; Gevensleben H; Tolkach Y; Sailer V; Majores M; Jung M; Meller S; Stein J; Ellinger J; Dietrich D; Kristiansen G
    J Mol Diagn; 2017 Jan; 19(1):107-114. PubMed ID: 27939865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
    Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
    Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
    Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
    Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
    Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
    Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy.
    Li X; Zhang W; Song J; Zhang X; Ran L; He Y
    Clin Epigenetics; 2019 Jul; 11(1):99. PubMed ID: 31288850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer.
    Strand SH; Hoyer S; Lynnerup AS; Haldrup C; Storebjerg TM; Borre M; Orntoft TF; Sorensen KD
    Clin Epigenetics; 2015; 7():111. PubMed ID: 26478752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and prognosis potential of four gene promoter hypermethylation in prostate cancer.
    Li Y; Meng L; Shi T; Ren J; Deng Q
    Cell Biol Int; 2021 Jan; 45(1):117-126. PubMed ID: 32991011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
    Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
    Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.